Vol. 5 No. 3 (2025)
Reimbursement Reviews

Alectinib (Alecensaro)

decorative image of the issue cover

Published March 5, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses alectinib (Alecensaro), 150 mg capsules, oral.
  • Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIAa ALK-positive non–small cell lung cancer.